Literature DB >> 19729346

Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.

Monique M Cherrier1, John K Amory, Mary Ersek, Linda Risler, Danny D Shen.   

Abstract

UNLABELLED: This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain. Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone). Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01). Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose. For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge. This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults. PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults. Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729346      PMCID: PMC2757528          DOI: 10.1016/j.jpain.2009.03.017

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  81 in total

Review 1.  The management of persistent pain in older persons.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2002-06       Impact factor: 5.562

2.  3MS normative data for the elderly.

Authors:  Tatyana G Jones; John A Schinka; Rodney D Vanderploeg; Brent J Small; Amy Borenstein Graves; James A Mortimer
Journal:  Arch Clin Neuropsychol       Date:  2002-02       Impact factor: 2.813

3.  Mild head injury and speed of information processing: a prospective study of professional rugby league players.

Authors:  A D Hinton-Bayre; G Geffen; K McFarland
Journal:  J Clin Exp Neuropsychol       Date:  1997-04       Impact factor: 2.475

4.  Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.

Authors:  James P Zacny
Journal:  Psychopharmacology (Berl)       Date:  2002-10-29       Impact factor: 4.530

5.  Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure.

Authors:  A M Elliott; B H Smith; W C Smith; W A Chambers
Journal:  Pain       Date:  2000-12-01       Impact factor: 6.961

6.  Relationship between the chronic pain grade and measures of physical, social and psychological well-being.

Authors:  K I Penny; A M Purves; B H Smith; W A Chambers; W C Smith
Journal:  Pain       Date:  1999-02       Impact factor: 6.961

7.  Exploring semantic memory by investigating buildup and release of proactive interference in healthy older adults and individuals with dementia of the Alzheimer type.

Authors:  Kristi S Multhaup; David A Balota; Mark E Faust
Journal:  J Int Neuropsychol Soc       Date:  2003-09       Impact factor: 2.892

Review 8.  Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions.

Authors:  Christian J Nelson; Nina Nandy; Andrew J Roth
Journal:  Palliat Support Care       Date:  2007-09

Review 9.  The cognitive effects of opioids.

Authors:  Mary Ersek; Monique M Cherrier; Steven S Overman; Gordon A Irving
Journal:  Pain Manag Nurs       Date:  2004-06       Impact factor: 1.929

10.  Mild cognitive impairment: applicability of research criteria in a memory clinic and characterization of cognitive profile.

Authors:  Suvarna Alladi; Robert Arnold; Joanna Mitchell; Peter J Nestor; John R Hodges
Journal:  Psychol Med       Date:  2006-01-23       Impact factor: 7.723

View more
  20 in total

1.  The effects of acute and chronic steady state methadone on memory retrieval in rats.

Authors:  Erin Cummins; Craig P Allen; Alexander Ricchetti; Emily Boughner; Kayla Christenson; Megan Haines; Cheryl L Limebeer; Linda A Parker; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2012-01-19       Impact factor: 4.530

2.  Undetected cognitive impairment and decision-making capacity in patients receiving hospice care.

Authors:  Cynthia Z Burton; Elizabeth W Twamley; Lana C Lee; Barton W Palmer; Dilip V Jeste; Laura B Dunn; Scott A Irwin
Journal:  Am J Geriatr Psychiatry       Date:  2012-04       Impact factor: 4.105

3.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

4.  Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 5.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

6.  Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.

Authors:  Gary Vorsanger; Jim Xiang; David Biondi; David Upmalis; Jacqueline Delfgaauw; René Allard; Bruce Moskovitz
Journal:  Pain Res Manag       Date:  2011 Jul-Aug       Impact factor: 3.037

7.  Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Neuropharmacology       Date:  2019-12-04       Impact factor: 5.250

8.  Oxycodone induced delirium and agitation in an elderly patient following total right knee arthroplasty.

Authors:  Joseph H Crane; Katie J Suda
Journal:  Int J Clin Pharm       Date:  2011-08-19

9.  Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

Authors:  Bruce Charles; Janet Hardy; Helen Anderson; Angela Tapuni; Rani George; Ross Norris
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

Review 10.  The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways.

Authors:  Eric L Garland; Brett Froeliger; Fadel Zeidan; Kaitlyn Partin; Matthew O Howard
Journal:  Neurosci Biobehav Rev       Date:  2013-08-26       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.